लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड और सिरोलिमस का इंटरैक्शन

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS ).

It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium. mTOR (mammalian target of rapamycin) inhibitors Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS ).

The concomitant use of sirolimus with other drugs known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors, may increase the risk of developing angioedema.

Elevated sirolimus levels (with/without concomitant ACE inhibitors) may also potentiate angioedema [ see Drug Interactions (7.2) ].